Posts Tagged: drug development
TIAP and Evotec Expand LAB150 Bridge Partnership to Include Amgen
TIAP announced today the significant expansion of its flagship LAB150 drug discovery and development program with the addition of Amgen as a strategic and financial partner. Read full press release: https://bwnews.pr/3D3DUXb
LAB150 was created in 2017 with Evotec as the first North American BRIDGEs program to accelerate the development of novel therapeutics from our Members. Today’s announcement not only provides pre-seed capital of US$14M to these emerging drug development projects but also significant expertise and mentorship to our local scientists and innovators from ...
Read more
Webinar: Staying on Target – How to Determine if Your Research Program is Ready for Drug Delivery
Staying on Target: How to Determine if Your Research Program is Ready for Drug Discovery
LAB150 Presents: A 3-part Webinar Series on Drug Discovery and Development
November 17, 2020 - 12-1:30 PM ET
Click here to hear a recording of the webinar: http://bit.ly/2O5dDR4
In the first of three webinars in the LAB150 series on drug discovery and development, we focus on the initial steps on the long path of bringing a new drug to market and to patients in need. Specifically, we examine approaches to target ...
Read more
Triphase announces positive results of phase 1 trial of Marizomib and Bevacizumab in malignant glioma
TORONTO and SAN DIEGO (June 4, 2016) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced positive results from its Phase 1 proof-of-concept study evaluating marizomib in combination with bevacizumab in patients with WHO grade IV malignant glioma.
These results were presented in a poster session during the American Society for Clinical Oncology (ASCO) annual meeting in Chicago on June 4, 2016.
“These results confirm our original hypothesis that this combination therapy is ...
Read more
Israel’s BioLineRx and Canada’s MaRS Innovation sign framework collaboration agreement
Agreement signed as part of Ontario's life sciences trade mission to Israel
TEL AVIV and TORONTO (May 16, 2016) – BioLineRx Ltd. a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed a framework collaboration agreement with MaRS Innovation, the commercialization agent for 15 of Toronto's top academic institutions.
Under the terms of the agreement, BioLineRx intends to review innovative projects and assets of start-up companies originating from MaRS Innovation's members to identify in-licensing, co-development or other ...
Read more
Triphase Accelerator Corporation expands collaboration with Celgene in developing Marizomib to treat gliomas
Company initiating two new clinical trials for recurrent and newly diagnosed malignant gliomas
TORONTO and SAN DIEGO, (May 03, 2016) – Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that it is expanding its current collaboration with Celgene Corp. in the development of marizomib for the potential treatment of malignant gliomas.
The two companies will collaborate on a Phase 2 study using marizomib (MRZ) as monotherapy in recurrent glioblastoma, as well as a Phase ...
Read more
Triphase secures FDA orphan drug designation for Marizomib in Malignant Glioma
TORONTO and SAN DIEGO (November 19, 2015) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for marizomib to treat patients with malignant glioma.
Malignant glioma is an aggressive form of brain cancer for which there is a significant unmet need in current treatments due to the disease's poor prognosis. Triphase is evaluating marizomib, a novel and highly ...
Read more
Global University Venturing features MaRS Innovation’s unique model for technology transfer
MaRS Innovation's "model solves the two weakest points in tech transfer: the lack of dealflow and the ability to match public funding," writes Thierry Heles in, "MaRS Innovation: A Unique Model for Tech Transfer," for Global University Venturing.
This feature was also covered in Techopia.
The article, which includes an interview with Dr. Rafi Hofstein, president and CEO of MaRS Innovation, was published September 14, 2015.
Here's an excerpt exploring the range of MI's portfolio and Hofstein's strategy for addressing technologies emerging in new ...
Read more
MI’s head of imaging technologies quoted on bioprinting in U.K.’s Financial Times
Fanny Sie, MaRS Innovation's head of imaging technologies, was quoted in Tanya Powley's article, "Printing whole organs remains a long way off," for the U.K.'s Financial Times on June 11, 2015, regarding the technology's potential to transform existing healthcare practices.
MI does wish to note that the article inaccurately attributes the PrintAlive device's development to MaRS Innovation; MI is working with the University of Toronto inventing team, led by Dr. Axel Gunther, to commercialize the device.
Here's a short excerpt:
Bioprinting could save pharmaceutical ...
Read more
Encycle Therapeutics developing lead molecule to tackle inflammatory bowel disease
Company's collaborative partnership with IRICoR, Université de Montréal and MaRS Innovation, funded by Merck Canada, to advance macrocycle drug
TORONTO and MONTREAL, Nov. 10, 2014 — Encycle Therapeutics Inc., a biotechnology start-up founded by Dr. Andrei Yudin of the University of Toronto in partnership with MaRS Innovation, is developing its lead orally-bioavailable macrocycle drug to target integrin a4b7, which is involved in the inflammatory process in a number of diseases, most notably for inflammatory bowel disease.
This announcement was covered in SciBX, Drug Discovery ...
Read more
Triphase announces Celgene collaborations and license deal with PharmAbcine
Triphase Accelerator Corporation, a private, drug development company dedicated to advancing novel compounds through Phase II proof-of-concept, announced October 27, 2014 new and expanded strategic collaborations with Celgene Corporation.
This announcement was covered in Genetic Engineering and Biotechnology News (GEN), BioCentury Extra (no link available), Pharmaceutical Business Review (no link available), Scrip and BioWorld Today (no link available). It builds on Triphase's original collaborative agreement with Celgene in January 2014.
The company has also announced a new global license for a fully human, bi-specific ...
Read more